Provider status has been three years away for about fifteen years, so scepticism is earned. But 2026 has produced real movement, and the movement is narrower and more specific than the phrase “provider status” suggests. Knowing exactly what is on the table matters, because the preparation that pays off is different from the preparation the slogan implies.
What is true today
Pharmacists are still not recognised practitioners under Medicare Part B. There is no direct billing pathway under the physician fee schedule for pharmacist professional services, and nothing that happened in the first half of 2026 changed that.
What exists instead is a set of narrow workarounds, each with real limits:
Incident-to billing. In a physician practice, a pharmacist’s service can be billed incident to the physician. CMS has been explicit that pharmacist-provided services are billable only at 99211, the lowest-level established patient E/M code, regardless of the complexity of what was actually done. It also requires direct supervision, meaning a physician or non-physician practitioner present in the office suite and immediately available, with the physician having established the plan of care and remaining actively involved. None of that describes a community pharmacy, which is why incident-to is largely irrelevant to independents.
Mass immunizer roster billing. A genuine Part B pathway, provider specialty type 73, for influenza and pneumococcal vaccination. Useful, and narrow.
Part D. Vaccines and drugs on the pharmacy benefit, plus MTM as a plan-administered programme rather than a fee-for-service benefit.
MTM CPT codes. 99605, 99606 and 99607 exist and are pharmacist-specific: 99605 for the initial 15 minutes with a new patient, 99606 for the initial 15 minutes with an established patient, and 99607 for each additional 15 minutes. Medicare Part B does not pay them. Some state Medicaid programmes and some commercial contracts do. They are time-based, and the time has to be documented.
PREP Act authority. The twelfth amendment to the COVID-19 PREP Act declaration, issued in December 2024, extended federal authority for pharmacists, pharmacy interns and qualified pharmacy technicians to independently administer COVID-19 vaccines and seasonal influenza vaccines and to order and administer COVID-19 tests through 31 December 2029. This is liability protection and authority. It is not a payment mechanism, and conflating the two is a common and expensive mistake.
What actually moved in 2026
Two distinct things happened, and they are frequently reported as one.
The Consolidated Appropriations Act of 2026 was signed on 3 February 2026 and carried substantial PBM reform. It requires CMS to define and enforce “reasonable and relevant” Medicare Part D contract terms, including terms on reimbursement and dispensing fees, and establishes a process for pharmacies to dispute them. From 1 January 2029, Part D sponsors must accept any pharmacy that agrees to those terms, with the Secretary due to define them by April 2028. It requires full pass-through of manufacturer rebates to plan sponsors, twice-yearly PBM reporting beginning in 2028 covering gross and net drug spend, rebates and spread pricing, and it carries penalties of up to $10,000 per day for reporting failures and up to $100,000 for knowingly false submissions.
That is significant law. It is not provider status, and almost all of it lands in 2028 and 2029.
Provider status legislation advanced but did not pass. H.R. 3164, renamed the Main Street Pharmacy Access Act (formerly the Ensuring Community Access to Pharmacist Services Act), cleared the House Ways and Means Committee on 21 May 2026. Its Senate companion is S. 2426. Notably, H.R. 3164 was not included in the Consolidated Appropriations Act of 2026.
Read the bill’s actual scope, because it is much narrower than “provider status”:
- It would provide Medicare Part B coverage for pharmacist-administered testing and treatment for four respiratory illnesses: COVID-19, influenza, RSV and streptococcal pharyngitis
- It would allow pharmacists to prescribe treatment for those conditions where clinically indicated
- It expressly does not preempt state scope of practice law
It is a test-and-treat bill, not a general professional services benefit. Chronic disease management, comprehensive medication review, and everything else you might want paid are not in it.
After Ways and Means, the bill was referred to the House Energy and Commerce Committee and has to clear that committee before any floor vote, then pass the Senate. Anyone telling you a date is guessing.
What is genuinely uncertain
Three things, and it is worth being honest about all of them.
- Whether the bill passes at all, and in what form. Committee passage is meaningful and is not enactment. Scope routinely narrows between markup and law.
- The payment rate. Non-physician practitioners are frequently paid a percentage of the physician fee schedule, but the operative rate for pharmacist services would be set in final legislation and subsequent rulemaking. Any figure quoted today is speculation.
- What your state permits. Federal payment status and state authority are separate questions. Even if Medicare pays for strep test-and-treat, you can only do it if your practice act and any required protocol or collaborative practice agreement allow it. State rules on independent prescribing, testing authority and protocol scope vary widely, and that variation will not be resolved by a federal bill that explicitly declines to preempt it.
What to do now that is worth doing regardless
The preparation that has value is preparation that pays off whether or not H.R. 3164 becomes law, because most of it is what commercial payers and state Medicaid already require.
Get the individual identifiers in place. Type 1 NPI for every pharmacist, correct pharmacist taxonomy, a CAQH profile attested every 120 days, and consistent name and address data across NPPES, CAQH and every payer file. This is slow, free, and useless to start after a bill passes.
Build documentation habits now. A billable clinical encounter needs a chief complaint, an assessment, a plan, an ICD-10 code, the time spent where the code is time-based, the rendering pharmacist, and consent. If your clinical documentation lives in a paper log or a free-text note, the transition later will be painful. The HL7 and NCPDP Pharmacist eCare Plan exists precisely to structure this, and is already supported by several pharmacy platforms.
Sort CLIA before you need it. A certificate of waiver takes weeks and is a prerequisite for the exact test-and-treat services the bill covers. Getting it now costs little and removes the longest lead item.
Chase the payers that already pay. Some state Medicaid programmes and commercial plans reimburse pharmacist services today. Those contracts are available now, they build the operational muscle, and they do not depend on Congress.
Do not restructure the business around it. Committee passage is not a revenue forecast. If a service line only works on the assumption that Medicare will pay for it in 2027, it is not a service line, it is a bet.
The useful framing is that provider status, if it arrives, changes who pays, not whether you can operate a billable service. Everything about being able to operate one, the identifiers, the enrollments, the documentation, the CLIA certificate and the denial workflow, is buildable today. Attergo Intelligence is designed to make that decision empirical rather than hopeful, modelling what a clinical service line is actually worth against your own claim and dispensing history before you commit staff hours to it.
Sources and further reading
- Congress.gov, S. 2426, Equitable Community Access to Pharmacist Services Act (119th Congress)
- AMCP, House Ways and Means Committee Advances H.R. 3164, the Main Street Pharmacy Access Act
- NCPA, House committees pass two NCPA policy priority bills, 22 May 2026
- Federal Register, Twelfth Amendment to the PREP Act Declaration for COVID-19 Medical Countermeasures
- ASHP, Incident-to Billing under Medicare Part B